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Abstract
Chronic spontaneous urticaria (CSU) is a disease that makes people’s lives miserable 
with unknown etiology. In recent years, there have been many studies trying to explain 
the etiology of CSU, and many of them reported that there are some comorbidities or trig-
gering factors related to CSU. However, it has not been clearly known yet that whether 
these conditions are true comorbidities associated with CSU or they are coincidentally 
found at the same time. In this chapter, related comorbidities and conditions have been 
told.
Keywords: chronic spontaneous urticaria, autoimmunity, infectious diseases, 
psychological comorbidities, coagulation factors, metabolic syndrome
1. Introduction
Chronic spontaneous urticaria (CSU) is a common mast cell-driven skin disorder characterized by 
the occurrence of recurrent and spontaneously daily or frequent wheals with or without angio-
edema, for more than 6 weeks with symptoms present at least three times weekly [1, 2]. CSU affects 
0.1–5% of the population, especially during the third and fourth decades and predominantly women 
[3]. There are many studies that some disorders or conditions may be related to CSU.
2. Comorbidities and possible triggering factors
There are studies showing that CSU affects not only the skin but also the life quality and psy-
chology of the person. At the same time, there has been a relation between CSU and other 
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diseases which can be based on similar pathogenesis such as autoimmune thyroiditis. After 
these data researches have mainly focused on the relationship between comorbidities and CSU.
The possible mechanisms and triggering factors underlying CSU have been identified as 
acute or chronic infections, stress, nonallergic hypersensitivity reactions to foods and drugs 
(pseudoallergic), and autoreactivity including autoimmunity mediated by functional autoan-
tibodies directed against the IgE receptor [4]. Stress is a major triggering and risk factor along 
CSU patients [5]. Furthermore, several studies revealed that stress can trigger or aggravate 
some skin diseases by the alternation of the functions of T cells and local neuroimmunoendo-
crine circuitry [6]. Most of the patients with CSU experience a stressor event within 6 months 
before the onset of the symptoms [7].
CSU patients have a higher level of stressful life events, perceived stress, and psychiatric 
comorbidity [7]. And many studies have shown that CSU patients more frequently have psy-
chiatric comorbidities [7–11]. The most common psychiatric situations in these patients are 
depression, somatoform, and anxiety disorders [11, 12]. Both these disorders and CSU symp-
toms could affect the quality of life (QoL) of the patients. Also, it was shown that CSU patients 
had lower social relationship scores compared to healthy controls [8, 11]. CSU patients report-
edly suffer more sleep disturbance, fatigue, emotional upset, and physical and mental restric-
tions at home and work [8]. Furthermore, in a study which compared patients with CSU to 
patients with psoriasis, physical impairment and effects of the disorder on QoL were found 
higher in patients with CSU than patients with psoriasis [13]. In a study QoL impairment in 
CSU patients was found higher than in patients with vitiligo [14]. Interestingly, Staubach et al. 
reported no significant relation between impact of QoL and age-sex, concurrent angioedema, 
and duration of CSU condition of the patients [8]. They also reported that the severity of 
the concomitant depression-anxiety or somatoform disorders in patients with CSU is impor-
tant, because these patients, with concomitant severe psychiatric conditions, had significant 
impairment of QoL than patients with CSU who did not exhibit psychiatric comorbidity. 
Moreover, these psychiatric problems could be the primary factors in these patients or might 
arise as psychosocial consequences of underlying dermatological disorders [8]. As a result, an 
interdisciplinary approach that combines dermatological and psychiatric treatments is neces-
sary for the management of CSU.
In recent years, associations between CSU and autoimmunity have been increasingly rec-
ognized in many studies [15–19]. Approximately 30–50% of patients with chronic urticaria 
produce specific IgG antibodies against the alpha subunit of the mast cell IgE receptor, and 
approximately 5–10% produce IgG antibodies against IgE itself [15]. Autoimmune mecha-
nisms have been proposed as responsible for the development of some of the cases. Especially, 
intradermal autologous serum injections were applied, and urticarial responses were seen in 
60% of patients with CSU [16].
Also, subsequent studies revealed that anti-IgG and anti-IgE autoantibodies, anti-FcεRI tar-
geted at basophils, and mast cells were found in 45–55% of patients with CSU. These auto-
antibodies bind to mast cell-bound IgE molecules or surface IgE receptors to stimulate and 
eventually degranulate the cells and cause the urticarial symptoms [17–19]. It was suggested 
that some CSU patients have an autoimmune mechanism induced by these autoantibodies [20].
A Comprehensive Review of Urticaria and Angioedema84
Thyroid diseases, especially Hashimoto’s disease in which production of thyroid autoanti-
bodies (antithyroid peroxidase antibodies and antithyroglobulin antibodies) and lympho-
cytic infiltration into the thyroid gland are seen, are the most common autoimmune diseases 
accompanying patients with CSU [19–21]. The etiology of thyroid autoimmunity is not 
known, but the genetic susceptibility and environmental factors are thought to initiate the 
process [22]. Leznoff and Sussman reported that 15% of the CSU patients had thyroid auto-
antibodies and there has been a relation between CSU and thyroid autoimmunity. The rate 
of high antithyroid antibodies in the patients with CSU ranges from 6.5% up to 57% in the 
other reports [23, 24]. The mechanism of these associations is not known. Confino-Cohen 
et al. hypothesized that the relationship between thyroid diseases and CSU might be based 
on shared susceptibility to autoimmune or chronic inflammatory processes [21]. Moreover, 
many small patient series and case reports reported that patients with CSU and thyroid auto-
immunity benefit from levothyroxine sodium or antithyroid drug treatment. In these studies, 
clinical remission of chronic urticaria was seen, whereas no change has been demonstrated in 
thyroid antibody levels [25–27].
Although autoimmune thyroid disorders have been investigated in CSU, its relation with 
other autoimmune diseases has been investigated less [20]. But there is a fact that if there is an 
autoimmune disease in a patient, the second or third autoimmune disease more often appears 
even if the patient is under immunosuppressive treatment [21]. And rheumatoid arthritis (RA) 
was found as the second most common autoimmune disease in patients with CSU. Confino et 
al. reported that RA was found 13 times more in patients with CSU than healthy controls [21]. 
Rheumatoid factor was found significantly more often in patients with CSU [28].
In a small series of patients or case reports, celiac disease was reported higher in patients with 
CSU [29]. Several case reports revealed a 1.5–7-fold increased risk of urticaria in patients with 
celiac disease [30–32]. Also, systemic lupus erythematosus (SLE) and type I diabetes mellitus 
were each found significantly more prevalent in female patients with CSU [21, 33, 34].
Patients with CSU were found to have a significantly 15 times higher risk of developing SLE as 
compared to the control group. Furthermore, SLE was found to be 25 times higher in women 
than in men with CSU or women of the control group [21].
The high prevalence of these autoimmune diseases in patients with CSU makes it thinkable 
that somehow CSU can be also a member of autoimmunity. But the underlying mechanism 
of autoimmunity related to urticaria has not been known yet, but as mentioned before, sus-
ceptibility to autoimmune and/or chronic inflammatory processes might be the reason [21].
In the last few years, many researches published about the activation of the coagulation 
system in patients with CSU. A study revealed that the levels of plasma prothrombin frag-
ment (PF)1+2, a marker of thrombin generation, were significantly increased in patients with 
CSU. They also reported that patients with CSU have more positive autologous plasma skin 
test result than a positive autologous serum skin test result. This study showed that there 
should be possible role of clotting factors in flaring symptoms induced by autologous plasma, 
because autoantibodies are equally present in serum and plasma [35]. Also, a statistically sig-
nificant relationship between elevated plasma levels of PF1+2 and D-dimer and the severity 
of CSU was reported in some studies [36, 37].
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CSU is characterized by the activation of the coagulation cascade [38, 39]. And it is probable 
that both intrinsic and extrinsic pathways are affected in CSU patients [40]. The coagulation 
system factors that most likely involved in the pathogenesis of CSU are tissue factor, throm-
bin, D-dimer, PF1+2, and activated factor VII [41, 42].
Thrombin activation, which is derived from platelets, directed investigations toward the eval-
uation of mean platelet volume (MPV) and CSU correlation. MPV is a potential marker of 
platelet reactivity because larger platelets are metabolically and enzymatically more active. 
It was shown that platelets secrete a large number of mediators of thrombosis, coagulation, 
inflammation, and atherosclerosis [43]. And MPV values were found significantly more in 
patients with CSU than the control group [21, 44]. A suggested possible way in the pathogen-
esis of CSU is that large activated platelets might activate the coagulation cascade. The activa-
tion of the coagulation pathways elicits increase in number of protease-activated receptor-1 
on mast cells, mediator degranulation from mast cells and, increase in vascular permeability 
[45–47]. In many studies, this activated coagulation cascade was found associated with more 
severe disease [40, 41, 47]. Also, some studies showed that coagulation factors decreased to 
normal limits after disease remission or during treatment [35, 36, 40]. In contrast to this view, 
some authors suggest that the activation of the coagulation cascade seems a potential inten-
sifying mechanism in the pathogenesis of CSU but is quite likely not the main trigger of the 
disease [47].
Chronic persistent infections,( e.g., Helicobacter pylori (Hp), streptococci, staphylococci, yer-
sinia, Giardia lamblia, Mycoplasma pneumoniae, Hepatitis viruses, Norovirus, Parvovirus B19, 
Anisakis simplex, Entamoeba spp., and Blastocystis spp.) have been suspected to be triggering 
factors in patients with CSU [3]. Especially, Hp infection was popularly investigated in the 
pathogenesis of CSU [48, 49]. It is thought that Hp infections could be a triggering factor in 
underlying autoimmune pathology of CSU [50], and there are studies showing that Hp infec-
tion is related to production of autoreactive IgM and IgG3 antibodies [51]. Another suggestion 
is that Hp-associated lipoprotein 20 (lpp20) could act as an antigen that is involved in molecu-
lar mimicry to mast cells, T cells, and B cells as well [51–53]. Also in some studies, eradication 
of Hp infection resulted in remission of CSU symptoms [54, 55].
CSU is histopathologically characterized by infiltrating perivascularT cells, eosinophils, and 
neutrophils, and neutrophils, and several studies reported that circulating levels of C-reactive 
protein (CRP), pro-inflammatory cytokines such as interleukin (IL)-6 and TNF-α, and matrix 
metalloproteinase 9 (MMP-9) have been found increasing in patients with CSU. Also, these 
markers are thought to appear to correlate with clinical activity score and severity of urticaria 
[56–58]. Metabolic syndrome (MetS) involves dyslipidemia, central obesity, glucose intoler-
ance, and high blood pressure [59]. Furthermore it has been reported that patients suffering 
from MetS had higher serum levels of inflammatory markers such as IL-1, IL-6, TNF, and CRP 
than healthy controls [60].
In a study, the prevalence of MetS was reported higher among the patients with CSU. Thus, 
systemic inflammation promoted by MetS may play a role in CSU pathogenesis as well. 
Furthermore, some studies revealed that the levels of TNF and C3 were found significantly 
higher and correlated with more severe, uncontrolled urticaria symptoms in patients with 
CSU and MetS at the same time [59, 60].
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Some studies showed that activation of eosinophils which are sources of vascular endo-
thelial growth factor and tissue factor in lesional skin of patients with CSU may play a 
role in the pathogenesis of CSU [61]. Elevated serum eosinophilic cationic protein levels 
were found correlated with symptoms in patients with CSU and MetS. Both diseases, CSU 
and MetS, which may mutually trigger or exacerbate each other, have elevated systemic 
inflammation [60].
3. Conclusion
Studies investigating comorbidities associated with CSU have been increasing in recent years, 
and new disorders possibly associated with the CSU have been reported. It has not been 
clearly known yet that whether these conditions are true comorbidities associated with CSU 
or they are coincidentally found at the same time. This will be clearer as more studies on the 
subject are added.
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